News | May 05, 2026
NIFTY Pharma remains resilient amid mixed market sentiment
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Keeps Halo Pharma to drive independent growth
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The approval was driven by data from the Phase III TULIP-SC trial
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Subscribe To Our Newsletter & Stay Updated
